An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

Part of paid clinical trials in Sarasota, Florida.

Sponsor
Annexon, Inc.
Study ID
NCT07807969
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vonaprument — DRUG
    Form: solution for injection; Route of Administration: IVT injection

Study Details

The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.

Key Dates

First listed
Sep 8, 2026
Start date
Sep 30, 2026
Status verified
Sep 2026
Primary completion
Jul 31, 2029
Completion
Jul 31, 2029

Study Design

Enrollment
605 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vonaprument
    Participants will receive vonaprument IVT injections every month for 24 months.

Primary Outcome Measure

Number of Participants with Treatment Emergent Adverse Events [ Time Frame: Through Month 24 ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Retina Group of FloridaSarasotaFlorida34233-
Retina Vitreous Associates of FloridaSt. PetersburgFlorida33711-
Cumberland Valley Retina ConsultantsHagerstownMaryland21740-
Mid Atlantic Retina SpecialistsHagerstownMaryland21740-
Retina Research Institute at New England Retina ConsultantsSpringfieldMassachusetts01107-
Asheville Eye Associates - Retina DivisionAshevilleNorth Carolina28803-
Verum Research, LLCEugeneOregon97401-

Find similar trials in Sarasota, FL

Related Studies